50 min listen
Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging
Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging
ratings:
Length:
82 minutes
Released:
Jan 17, 2024
Format:
Podcast episode
Description
Dr Joan Mannick is one of the world’s leading rapamycin and mTOR researchers in the longevity field. Joan has a background in academic medicine and is currently CEO at her own company Tornado Therapeutics where they focus on developing the next generation of mTOR inhibitors. One of the company goals is to create a mTOR inhibitor which is better than Rapamycin. Throughout the years Joan has made important discoveries in humans when it comes to finding a connection between mTOR inhibition and improvement of the aging immune system. In this podcast we are going to talk about her research, drug development, mTOR, rapamycin, rapalogs and other interesting longevity topics.Linkshttps://www.tornado-tx.comJoan's LinkedInJoan’s research publicationsBig thanks to TimePie for the research help for this episodeRapamycin resourcesRapamycin.newsRapamycin Facebook groupRapamycin Reddit groupConnect with Krister on:TwitterLinkedInInstagramDisclaimer: The podcast is for general information and educational purposes only and is not medical advice for you or others. The use of information and materials linked to the podcast is at the users own risk. Always consult your physician with anything you do regarding your health or medical condition.
Released:
Jan 17, 2024
Format:
Podcast episode
Titles in the series (8)
Ross Pelton on Rapamycin Master Series | How it all began by Master One Thing - Rapamycin Longevity Series